Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34− cell preparations

Gao, Zhigang; Fackler, Mary Jo; Leung, Wing; Lumkul, Rachata; Ramírez, Manuel; Theobald, Narda; Malech, Harry L.; Civin, Curt I.

doi:10.1016/s0301-472x(01)00654-3

Cited by 48 publications

(54 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, secondary reconstitution capability existed exclusively in the CD34 + population. These results are in complete agreement with the studies of murine stem cells and are consistent with the previous report by Gao et al, 8 who used NOD/SCID mice and analyzed the engraftment levels at 8 weeks. We also tested the expression of CD38 by human CB stem cells.…”

Section: Figuresupporting

confidence: 93%

Human cord blood long-term engrafting cells are CD34+ CD38−

et al. 2003

View full text Add to dashboard Cite

There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/b2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34 + population. The capability of secondary reconstitution was found only in the CD34 + cells. When the CD34 + CB cells were separated into CD38 À and CD38 + subpopulations and tested for engraftment, the majority of the engrafting cells were detected in the CD38 À subpopulation. These findings are consistent with the results from studies of murine stem cells and strongly indicate that the phenotype of human CB stem cells is CD34 + CD38 À . Leukemia (2003) 17, 960-964.

show abstract

Section: Figuresupporting

confidence: 93%

Human cord blood long-term engrafting cells are CD34+ CD38−

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Also, the coexpression of subpopulation with other markers, such as Sca-1 and c-kit, [61][62][63][64] as compared with Lin − CD34 + /CD34 − cells does not seem to identify the same long-term repopulating capability cell population. 13,41,48,64,65 Early discrepancies with respect to results on CD34 + and CD34 − cells may also be due to the low but detectable levels of CD34 which can cause overlap in purified subsets. 12,14,41,[60][61][62][63][64][65][66][67][68] Differences in the sensitivity of the in vivo engraftment assays may also be related to the lack of administration of accessory cells, administration of cytokines to the transplanted mice, experimental manipulation of the HSC cell preparation and/or myeloablative treatment of mice.…”

Section: Potential Reasons For Diverse Results On Cd34 − and Cd34 + Hmentioning

confidence: 99%

CD34+ or CD34−: which is the more primitive?

2002

View full text Add to dashboard Cite

Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of hematopoietic cells and provide self-renewal, possess differentiation capacity and allow a constant supply of the entire hematopoietic cell spectrum. Until recently, CD34 has been used as a convenient marker for HSC, since CD34 ؉ cells have been shown to possess colony-forming potential in short-term assays, maintain long-term colony-forming potential in in vitro cultures and allow the expression and differentiation of blood cells from different hematopoietic lineages in in vivo models. Clinical and experimental protocols have targeted CD34 ؉ cells enriched by a variety of selection models and have readily used these for transplantation, purging and gene therapies and targets for future organ replacement. Recent studies in murine and human models, however, have indicated that CD34 ؊ HSC exist as well, which possess engraftment potential and distinct HSC characteristics. These studies challenge the dogma that HSC are uniformly found in the CD34 ؉ subset, and question whether primitive HSC are CD34 ؉ or CD34 ؊ . In this review, results on murine and human CD34 ؉ and CD34 ؊ HSC, differences between them and their possible interactions are examined.

show abstract

“…Controversies then rapidly appeared by other groups suggesting limited hematopoietic engraftment potential to Lin -CD34 -cells when compared with Lin -CD34 + HSPC [12,13]. These investigators then hypothesized that small numbers of contaminating CD34 + HSPC could account for CD34 -cell engraftment to the marrow [13].…”

Section: ® Original Articlementioning

confidence: 99%